BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30459282)

  • 1. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lineage of origin in rhabdomyosarcoma informs pharmacological response.
    Abraham J; Nuñez-Álvarez Y; Hettmer S; Carrió E; Chen HI; Nishijo K; Huang ET; Prajapati SI; Walker RL; Davis S; Rebeles J; Wiebush H; McCleish AT; Hampton ST; Bjornson CR; Brack AS; Wagers AJ; Rando TA; Capecchi MR; Marini FC; Ehler BR; Zarzabal LA; Goros MW; Michalek JE; Meltzer PS; Langenau DM; LeGallo RD; Mansoor A; Chen Y; Suelves M; Rubin BP; Keller C
    Genes Dev; 2014 Jul; 28(14):1578-91. PubMed ID: 25030697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
    Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
    J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
    J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.
    Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD
    Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH
    Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
    Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
    Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
    Jothi M; Mal M; Keller C; Mal AK
    Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
    Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
    J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.
    Thalhammer V; Lopez-Garcia LA; Herrero-Martin D; Hecker R; Laubscher D; Gierisch ME; Wachtel M; Bode P; Nanni P; Blank B; Koscielniak E; Schäfer BW
    Cancer Res; 2015 Jan; 75(1):98-110. PubMed ID: 25398439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.
    Dietz KN; Miller PJ; Iyengar AS; Loupe JM; Hollenbach AD
    Int J Biochem Cell Biol; 2011 Jun; 43(6):936-45. PubMed ID: 21440083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.
    Marshall AD; Lagutina I; Grosveld GC
    Cancer Res; 2011 Dec; 71(24):7471-80. PubMed ID: 22037868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
    Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J
    Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.
    Marshall AD; van der Ent MA; Grosveld GC
    Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
    Li L; Sarver AL; Alamgir S; Subramanian S
    Lab Invest; 2012 Apr; 92(4):571-83. PubMed ID: 22330340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.